We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

A Novel Liquid Biopsy Spectroscopy Method for Early Detection of Brain Tumors

By LabMedica International staff writers
Posted on 16 Aug 2021
Print article
Image: Highly effective early diagnostic tests could revolutionize cancer detection.  Here, a sample is dropped onto a disposable Dxcover Slide and dried for analysis (Photo courtesy of Dxcover Limited)
Image: Highly effective early diagnostic tests could revolutionize cancer detection. Here, a sample is dropped onto a disposable Dxcover Slide and dried for analysis (Photo courtesy of Dxcover Limited)
A blood-based liquid biopsy approach enables detection of brain tumors that are so small and low-grade that the patient will often have few or no symptoms.

Due to the non-specific symptoms of brain cancer, gliomas will often remain undetected until they are larger or at a higher grade, reducing the patient’s likelihood of a good clinical outcome. Earlier detection and diagnosis of brain tumors is vital to improve patient outcomes, leading to safer surgeries and earlier treatments.

In this regard, investigators at the University of Strathclyde (Glasgow, United Kingdom) and the biotech company Dxcover Limited (Glasgow, United Kingdom) developed a Multi Cancer Early Detection (MCED) Platform based on a spectroscopic liquid biopsy approach for detection of small and low-grade gliomas.

This approach combined attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy coupled with supervised learning methods and machine learning algorithms for the analysis of dried blood samples.

The current study was carried out on a cohort of 177 patients (90 patients with high-grade glioma (glioblastoma (GBM) or anaplastic astrocytoma), or low-grade glioma (astrocytoma, oligoastrocytoma, and oligodendroglioma). Tumor volumes were calculated from magnetic resonance imaging (MRI) investigations and patients were split into two groups depending on MRI parameters. Combining the spectroscopy technology with supervised learning methods and machine learning algorithms, 90 tumor patients were stratified against 87 control patients who displayed no symptomatic indications of cancer, and were classified as either glioma or non-glioma.

Results revealed that sensitivities, specificities, and balanced accuracies were all greater than 88%, the area under the curve (AUC) was 0.98, and cancer patients with tumor volumes as small as 0.2 cubic centimeters were correctly identified.

Senior author Dr. Matthew Baker, chief technical officer of Dxcover Limited, said, "This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumors, which is great news for the care of future brain cancer patients, increasing treatment options and potentially extending life expectancy. Clinical tests like this are a crucial part of Dxcover's journey to develop and commercialize a widely accepted Multi-Cancer Early Detection platform to help save lives."

The liquid biopsy for early glioma detection was described in the July 30, 2021, online edition of the journal Cancers.

Related Links:
University of Strathclyde
Dxcover Limited


New
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM
New
Gold Supplier
SARS-CoV-2 Variants Assay
Novaplex SARS-CoV-2 Variants IV Assay
New
Laboratory Information System (LIS)
GLIMS 10
New
Next-Generation Sequencing Platform
Clear Dx

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.